SD Biosensor stock: 2029 plan targets 1.2 trillion won revenue

Published on 11/04/2026 at 01:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

SD Biosensor stock is pursuing broader diagnostics growth and continued shareholder returns. Its strategy centers on overseas sales, molecular testing and global procurement.

Growth plan sets medium-term priorities

SD Biosensor is targeting broader international sales through rapid, molecular and automated immunodiagnostics.
Management plans to expand regulatory approvals, procurement access and recurring reagent revenue.
Shareholder returns are set to remain part of the strategy through dividends and treasury-share cancellations.

SD Biosensor stock, diagnostics, corporate strategy, molecular diagnostics, shareholder returns, Illustration mit AI erstellt.

SD Biosensor has set out a medium-term corporate-value plan aimed at expanding its diagnostics portfolio and improving profitability. The company disclosed the strategy on October 28, 2026, according to Biobook Media.

The plan focuses on rapid diagnostics, blood glucose testing, fluorescence immunoassays and molecular diagnostics. SD Biosensor said overseas direct sales had become a larger part of its commercial model and that net income returned to positive territory in the first half of 2026.

Regulatory access supports expansion

Management plans to increase the number of rapid diagnostic products with World Health Organization prequalification and to pursue additional sales through international procurement markets. The company also intends to expand the installed base and test menu for its STANDARD M molecular platform.

Further growth is tied to regulatory progress in Europe and the United States. SD Biosensor plans to pursue European market access under the In Vitro Diagnostic Medical Devices Regulation and US Food and Drug Administration registrations for selected molecular diagnostic products.

Returns remain part of strategy

The corporate-value plan also includes continued dividends and treasury-share cancellations through 2028. Interim dividends could be considered if business performance improves, while the company plans regular investor-relations briefings to present progress and gather shareholder feedback.

Business model and market position

SD Biosensor is a South Korean in-vitro diagnostics company headquartered in Suwon. Its portfolio includes STANDARD Q rapid tests, STANDARD F fluorescence immunoassay systems, STANDARD E enzyme-linked immunosorbent testing, STANDARD M point-of-care molecular diagnostics, STANDARD i automated immunodiagnostics and blood glucose meters.

The company serves healthcare and testing markets through products spanning near-patient testing and laboratory workflows. Its position is centered on a broad point-of-care and laboratory diagnostics portfolio, with international expansion and regulatory approvals shaping its competitive prospects.

SD Biosensor at a glance

Company: SD Biosensor, Inc.
Headquarters: Suwon, Gyeonggi-do, South Korea
Business: In-vitro diagnostics, molecular testing and blood glucose monitoring
Key platforms: STANDARD Q, STANDARD F, STANDARD E, STANDARD M and STANDARD i
Chief executive: Hyo Keun Lee